# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Soligenix (NASDAQ:SNGX) reported quarterly losses of $(1.31) per share which beat the analyst consensus estimate of $(1.77) by ...
PCG Digital -- Soligenix, Inc. (NASDAQ:SNGX), a late-stage biopharmaceutical company, is making significant strides in the trea...
Soligenix shares surged on heavy volume, following an interim update on the extended Hybryte treatment study.